FOR IMMEDIATE RELEASE

Novasite Pharmaceuticals Acquires Access to the OriGene TrueClone™ Collection

Rockville, MD February 15, 2005 – OriGene Technologies Inc. today announced that Novasite Pharmaceuticals has licensed a subscription access to their TrueClone™ Collection of 24,000 full-length human cDNAs suitable for transfection and high throughput functional analyses.

"We are pleased to formalize our relationship with OriGene. We have found their TrueClone collection to be the best answer to expanding needs within the pharmaceutical industry to access readily available full-length human cDNAs for multiple drug targets in a timely and reliable manner," said Juan Ballesteros, Chief Scientific Officer of Novasite. "The OriGene TrueClone collection will complement our endogenously expressed receptor cell lines and jumpstart our programs to screen families of GPCRs for allosteric modulators"

Novasite is an integrated pharmaceutical company focused on Structure-Function Drug Discovery. It has developed an integrated approach to enable the discovery of agonist & allosteric potentiator drugs targeting G-protein coupled receptors ("GPCRs"). When combined, these technologies form a direct link between structural information and functional data, enhancing Novasite's drug discovery efforts.

The OriGene TrueClone™ Collection of 24,000 cDNAs represents the world's largest commercial source of human full-length cDNAs. All transcripts in the TrueClone™ Collection are isolated directly from primary cDNA libraries, therefore devoid of PCR artifacts. Each cDNA clone is housed in expression vectors suitable for transfection and protein expression. The comprehensive nature of the TrueClone™ Collection and the uniformity and expression-readiness of the cloning vector uniquely enables a systems biology approach to high-throughput screening and functional studies.

"OriGene's mission is not only to build the most comprehensive collection of human full-length cDNAs, but also to make it a scientifically useful platform to enable systematic studies of human gene functions," said Karl Kovacs PhD, Vice President of Strategic Alliances at OriGene.

About OriGene Technologies

OriGene provides innovative technologies for large-scale gene function analyses. OriGene's flagship product is the TrueClone™ Collection, a searchable gene bank of over 24,000 human full-length cDNA clones suitable for transfection and protein expression. More information about OriGene Technologies and their products can be found at the company's web site at http://www.origene.com.

For additional information regarding this announcement, please contact:

Rich Hamer, Ph.D.
Business Development
OriGene Technologies 240-620-0267
rhamer@origene.com

About Novasite Pharmaceuticals

Novasite Pharmaceuticals has developed an integrated "Single Cell Structure-Function" approach to enable the discovery of allosteric modulators and difficult agonist drugs targeting G-Protein Coupled Receptors ("GPCRs"). Allosteric modulation is a novel and safer mechanism of action for GPCR drugs. This novel high-growth market has become a major focus for pharmaceutical companies because it combines the best mechanism of action of a drug with the most important family of drug targets, GPCRs. Novasite's proprietary approach is uniquely capable of solving the key technical challenges in discovering GPCR Allosteric Modulators; Single Cell Screening enables functional detection of these effects, and the Structure-Function approach provides structural information to guide medicinal chemistry. Furthermore, Novasite's breakthrough crystallography approach may enable elucidation of the complete 3D structures of these receptors. For more information, please visit www.Novasite.com.

For additional information regarding this announcement, please contact:

Kathryn Rucker, M.B.A.
V.P. of Finance and Corporate Development
Novasite Pharmaceuticals 858-875-8582
krucker@novasite.com